ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Приведен анализ различных данных по вопросам формировании иммунного ответа у больных COVID-19. Показано, что в целом иммунный ответ при COVID-19 развивается преимущественно по клеточному типу. Гуморальный иммунный ответ, связанный с продукцией вируснейтрализующих антител обеспечивает защиту от инфекции в дальнейшем. Интересной является установленная перекрестная реактивность сывороток крови больных COVID-19 и SARS. Рассмотрены вопросы популяционного иммунитета и длительности сохранения антител к SARS-Cov-2.
Бугоркова С. А. 2020. Некоторые аспекты формирования иммунного ответа у пациентов с COVID-19. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111717
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020 www.thelancet.com Published online January 24, 2020 https://doi.org/10.1016/S0140-6736(20)30183-5;
2. National Health Commission of the People’s Republic of China. Update on the novel coronavirus pneumonia outbreak (Feb 16, 2020). Available at: http://www.nhc.gov.cn/xcs/yqtb/202002/18546da875d74445bb537ab014e7a1c6.shtml.
3. A public health emergency of international concern over the global outbreak of novel coronavirus declared by WHO. Available at: https://www.who.int/dg/speeches/detail/whodirector-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov)
4. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32
5. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9
6. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Version 2. Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMID: 32221306;
7. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. PMID: 32142651
8. Vinh Q. Chau, Estefania Oliveros, Kiran Mahmood, Aditi Singhvi, Anuradha Lala Noah Moss, Umesh Gidwani, Donna M Mancini, Sean P Pinney, Aditya Parikh. The Imperfect Cytokine Storm: Severe COVID-19 With ARDS in Patient on Durable LVAD Support JACC Case Rep . 2020 Apr 8. doi: 10.1016/j.jaccas.2020.04.001;
9. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020 Jun;53:25-32. doi: 10.1016/j.cytogfr.2020.05.003. Epub 2020 May 11. PMID: 32446778
10. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020 Apr;87(4):281-286. doi: 10.1007/s12098-020-03263-6. Epub 2020 Mar 13. PMID: 32166607;
11. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020 Feb 21;323(14):1406-7. doi: 10.1001/jama.2020.2565. Online ahead of print. PMID: 32083643
12. Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., Tian D.S. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020 Mar 12. pii: ciaa248. doi: 10.1093/cid/ciaa248
13. Sheng Zhagn , Danping Li , Huazhong Chen , Dan Zheng, Yiping Zhou , Baoguo Chen , Weiwu Shi , Ronghai Lin. Dynamic Inflammatory Response in a Critically Ill COVID-19 Patient Treated With Corticosteroids. Case Reports. 2020; 25;49(2):220-226
14. Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, Xia WG, Zhang JX, Miao Q. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. J Infect. 2020 Jul;81(1):e51-e60. doi: 10.1016/j.jinf.2020.04.012. Epub 2020 Apr 18
15. Moro-Garcia MA, Alonso-Arias R, Lopez-Larrea C. When Aging Reaches CD4+ T-Cells: Phenotypic and Functional Changes. Front Immunol 2013; 4: 107
16. Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792-5
17. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2017; 137:82-92
18. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Preprint]. 2020 [cited 2020 Feb 15]: [15 p.]. Available from: https://doi. org/10.1038/s41586-020-2012-7
19. Eakachai Prompetchara,Chutitorn Ketloy, Tanapat Palaga Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol DOI 10.12932/AP-200220-0772
20. Quan-xin Long, Hai-jun Deng, Juan Chen et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. Preprint doi: https://doi.org/10.1101/2020.03.18.20038018
21. Juanjuan Zhao Jr. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Preprint · March 2020 with 694 Reads DOI: 10.1101/2020.03.02.20030189
22. Shu‐Yuan Xiao, Yingjie Wu, Huan Liu. Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring J Med Virol. 2020; 92: 464–467. DOI: 10.1002/jmv.25702;
23. Fatima Amanat, Thi Nguyen, Veronika Chromikova et al. A serological assay to detect SARS-CoV-2 seroconversion in humans препринт doi: https://doi.org/10.1101/2020.03.17.20037713
24. Li Guo, Lili Ren, Siyuan Yang , Meng Xiao et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Clin Infect Dis/ 2020 Mar 21 DOI: 10.1093/cid/ciaa310
25. Anu Haveri, Teemu Smura Suvi Kuivanen et al. Serological and Molecular Findings During SARS-CoV-2 Infection: The First Case Study in Finland, January to February 2020 Euro Surveill 2020 Mar;25(11):2000266. doi: 10.2807/1560-7917.ES.2020.25.11.2000266
26. Chen X, Zhou B, Li M, Liang X, Wang H, Yang G, et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis. 2004;189(7):1158-63. 10.1086/380397;
27. Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. 10.1016/S0140-6736(03)13412-5
28. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease. Pre-print. 2019medRxiv 2020.03.02.20030189.
29. Okba NMA, Müller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis 2020;26(7)
30. Tan W, Lu Y, Zhang J, et al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv March 26, 2020. doi:10.1101/2020.03.24.20042382
31. Wighton D, Chazan D. Germany will issue coronavirus antibody certificates to allow quarantined to re-enter society. Telegraph March 29, 2020. https://www.telegraph.co.uk/news/2020/03/29/ germany-will-issue-coronavirus-antibody-certificates-allow-quarantined/. Accessed April 17, 2020
32. Developing a National Strategy for Serology (Antibody Testing) in the United States (Contributors from Johns Hopkins University) https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/200422-national-strategy-serology.pdf
33. Tuzman KT. NCI takes lead on serological test validation as cancer center joins COVID-19 fight. BioCentury April 9, 2020. https://www.biocentury.com/article/304874. Accessed April 11, 2020
34. Hopper L. USC-L.A. County antibody testing may reveal when it’s safe to go back to work. USC News April 10, 2020. https://news.usc.edu/168497/antibody-testing-covid-19-pandemic-usc-losangeles-county/. Accessed April 17, 2020. 21.
35. McLaughlin E, Blankstein A. Large-scale COVID-19 antibody testing study launched in California. NBC News April 12, 2020. https://www.nbcnews.com/health/health-news/los
36. Carlos Brotons, Jordi Serrano, Diana Fernandez, Carlos Garcia-Ramos, Begona Ichazo, Jeannine Lemaire, Patricia Montenegro, Irene Moral, Ricky Perez- Wienese, Marc Pitarch, Mireia Puig, Maria Teresa Vilella, Jaume Sellares Seroprevalence against COVID-19 and follow-up of suspected cases in primary health care in Spain doi: https://doi.org/10.1101/2020.06.13.20130575
37. Xiao DAT, Gao DC, Zhang DS. Profile of specific antibodies to SARS-CoV-2: the first report. J Infect 2020 Mar 21. doi:10.1016/j.jinf.2020.03.012
38. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014;5:520
39. Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv April 20, 2020. doi:10.1101/2020.03.30.20047365
40. Müller MA, Corman VM, Jores J, et al. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997. Emerg Infect Dis 2014;20(12):2093-2095.
41. Tao Liu, Sanyun Wu, Huangheng Tao, Guang Zeng, Fuling Zhou, Fangjian Guo, Xinghuan Wang. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan - implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2 doi: https://doi.org/10.1101/2020.06.13.20130252
42. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. 2020:2020.03.13.990226
43. Wu L-P, Wang N-C, Chang Y-H, Tian X-Y, Na D-Y, Zhang L-Y, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562-4;
44. Guo X, Guo Z, Duan C, chen Z, Wang G, Lu Y, et al. Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers. 2020:2020.02.12.20021386.
45. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32
46. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9
47. Paul Kellam and Wendy Barclay. The dynamics of humoral immune responses following SARS- CoV-2 infection and the potential for reinfection. Journal of General Virology/ DOI/10/11099/jgv.0.001439
48. COVID-19-EPIDEMIC : Immunity after SARS-CoV-2 infection– a rapid review. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/immunity-after-sars-cov-2-infection-1st-update-report-2020.pdf
